Active substance
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older. Ivemend 150 mg is given as part of a combination therapy.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| EMEND IV | 02363356 | 150 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | MERCK CANADA INC |
| FOSAPREPITANT FOR INJECTION | 02549379 | 150 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | JUNO PHARMACEUTICALS CORP. |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.